Amarin Corp Plc (AMRN)

[Tatsumaki]

The most likely Amarin positive outcome of this trial is that Hikma gets told they should have disclaimed the use of the product for non labeled indications on the label itself. Perhaps some damages paid. Industry wide result, all future skinny label drugs, including the other EPA geneircs, will just include disclaimers on the label. Everyone down stream of the generic manufacturer; Dr's... insurers... patients... will continue to use it however they want for any end use. As codified by HW, skinny labels are 100% legal and by design, encouraged to force competition on branded drugs for the benefit of the US population. There will be no elimination of generic EPA across the board.

It's like a guy with a patent on ice yelling at everyone with a freezer in their house that they cant make ice.